Acetazolamide - PharmaKB

Acetazolamide

Acetazolamide (acetazolamide) is a small molecule pharmaceutical. Acetazolamide was first approved as Diamox on 1982-01-01. It is used to treat altitude sickness, glaucoma, and seizures in the USA. The pharmaceutical is active against carbonic anhydrase 7. In addition, it is known to target carbonic anhydrase 14, carbonic anhydrase 12, carbonic anhydrase 1, carbonic anhydrase 13, and carbonic anhydrase 4.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
respiratory tract diseases	D012140
nervous system diseases	D009422
eye diseases	D005128
signs and symptoms pathological conditions	D013568

Trade Name

FDA

EMA

Acetazolamide (discontinued: Acetazolamide, Diamox)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Acetazolamide

Tradename	Company	Number	Date	Products
DIAMOX	Teva	N-008943 DISCN	1982-01-01	2 products, RLD
DIAMOX	Teva	N-012945 DISCN	1982-01-01	1 products, RLD

Hide discontinued

Acetazolamide sodium

Tradename	Company	Number	Date	Products
DIAMOX	Teva	N-009388 DISCN	1982-01-01	1 products, RLD

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
acetazolamide	ANDA	2025-08-28
acetazolamide extended-release	ANDA	2025-01-09

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
altitude sickness	EFO_1000782	D000532	T70.29
glaucoma	EFO_0000516	D005901	H40
seizures	—	D012640	G40.4

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

S: Sensory organ drugs

— S01: Ophthalmologicals

— S01E: Antiglaucoma preparations and miotics

— S01EC: Carbonic anhydrase inhibitors, antiglaucoma drugs and miotics

— S01EC01: Acetazolamide

HCPCS

Code	Description
J1120	Injection, acetazolamide sodium, up to 500 mg

Clinical

Clinical Trials

178 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Altitude sickness	D000532	EFO_1000782	T70.29	4	2	3	18	6	32
Heart failure	D006333	EFO_0003144	I50	—	1	6	11	5	22
Obstructive sleep apnea	D020181	EFO_0003918	G47.33	3	10	1	4	1	16
Sleep apnea syndromes	D012891	EFO_0003877	G47.3	1	5	—	6	4	15
Chronic obstructive pulmonary disease	D029424	EFO_0000341	J44.9	—	—	3	9	—	12
Hypoxia	D000860	—	R09.02	1	—	1	9	1	12
Glaucoma	D005901	EFO_0000516	H40	—	—	1	3	2	6
Central sleep apnea	D020182	—	G47.31	—	3	1	2	—	6
Pulmonary hypertension	D006976	EFO_0001361	I27.20	—	3	3	2	—	6
Emphysema	D004646	EFO_0000464	J43	—	—	—	5	—	5

Show 32 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Pseudotumor cerebri	D011559	EFO_1001132	G93.2	1	1	3	—	3	7
Intracranial hypertension	D019586	EFO_1000992	—	1	1	2	—	4	7
Hypertension	D006973	EFO_0000537	I10	1	2	2	—	2	6
Stroke	D020521	EFO_0000712	I63.9	—	2	2	—	1	5
Headache	D006261	—	R51	—	—	2	—	1	3
Hypotension	D007022	EFO_0005251	I95	1	—	1	—	—	2
Syndrome	D013577	—	—	—	1	1	—	1	2
Retinal artery occlusion	D015356	EFO_1001154	H34.1	—	—	1	—	—	1
Hemodilution	D006438	—	—	—	—	1	—	—	1
Visual acuity	D014792	—	—	—	—	1	—	—	1

Show 13 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Macular edema	D008269	—	—	—	3	—	—	—	3
Cerebrospinal fluid leak	D065634	—	G96.0	—	3	—	—	—	3
Chronic pain	D059350	—	—	—	2	—	—	—	2
Macular degeneration	D008268	EFO_0001365	H35.30	—	2	—	—	—	2
Diabetic retinopathy	D003930	EFO_0003770	—	—	2	—	—	—	2
Brain edema	D001929	EFO_1000845	G93.6	—	1	—	—	1	2
Normal pressure hydrocephalus	D006850	EFO_1001065	G91.2	—	2	—	—	—	2
Neoplasms	D009369	—	C80	1	1	—	—	—	2
Melanoma	D008545	—	—	2	1	—	—	—	2
Type 1 diabetes mellitus	D003922	EFO_0001359	E10	1	2	—	—	—	2

Show 23 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	1	—	—	—	2	3
Obesity	D009765	EFO_0001073	E66.9	1	—	—	—	1	2
Pure autonomic failure	D054970	—	—	1	—	—	—	—	1
Orthostatic hypotension	D007024	—	I95.1	1	—	—	—	—	1
Glioma	D005910	EFO_0000520	—	1	—	—	—	—	1
Prostatic neoplasms	D011471	—	C61	1	—	—	—	—	1
Multiple endocrine neoplasia type 1	D018761	—	E31.21	1	—	—	—	—	1
Cognition	D003071	EFO_0003925	—	1	—	—	—	—	1
Exercise tolerance	D017079	—	—	1	—	—	—	—	1
Small cell lung carcinoma	D055752	—	—	1	—	—	—	—	1

Show 3 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Sickle cell anemia	D000755	EFO_0000697	D57	—	—	—	—	2	2
Migraine disorders	D008881	EFO_0003821	G43	—	—	—	—	2	2
Acute liver failure	D017114	—	—	—	—	—	—	2	2
Type 2 diabetes mellitus	D003924	EFO_0001360	E11	—	—	—	—	2	2
Cerebral infarction	D002544	—	I63	—	—	—	—	2	2
Dementia	D003704	EFO_0003862	F03	—	—	—	—	2	2
Headache disorders	D020773	EFO_0009550	G44	—	—	—	—	2	2
Tinnitus	D014012	—	H93.1	—	—	—	—	2	2
Thalassemia	D013789	EFO_1001996	D56	—	—	—	—	1	1
Nephrolithiasis	D053040	—	N20.0	—	—	—	—	1	1

Show 23 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Acetazolamide
INN	acetazolamide
Description	Acetazolamide is a sulfonamide, a member of thiadiazoles and a monocarboxylic acid amide. It has a role as a diuretic, an anticonvulsant and an EC 4.2.1.1 (carbonic anhydrase) inhibitor. It is a conjugate acid of an acetazolamide(1-). It derives from a hydride of a 1,3,4-thiadiazole.
Classification	Small molecule
Drug class	carbonic anhydrase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	CC(=O)Nc1nnc(S(N)(=O)=O)s1